Levels of Serum Resistin in Asthmatics as a Potential Marker of Systemic Inflammation and Disease State.
|ClinicalTrials.gov Identifier: NCT00339703|
Recruitment Status : Unknown
Verified May 2006 by Wilford Hall Medical Center.
Recruitment status was: Active, not recruiting
First Posted : June 21, 2006
Last Update Posted : June 21, 2006
|First Submitted Date||June 19, 2006|
|First Posted Date||June 21, 2006|
|Last Update Posted Date||June 21, 2006|
|Start Date||November 2004|
|Primary Completion Date||Not Provided|
|Current Primary Outcome Measures||Not Provided|
|Original Primary Outcome Measures||Not Provided|
|Change History||No Changes Posted|
|Current Secondary Outcome Measures||Not Provided|
|Original Secondary Outcome Measures||Not Provided|
|Current Other Outcome Measures||Not Provided|
|Original Other Outcome Measures||Not Provided|
|Brief Title||Levels of Serum Resistin in Asthmatics as a Potential Marker of Systemic Inflammation and Disease State.|
|Official Title||Levels of Serum Resistin in Asthmatics as a Potential Marker of Systemic Inflammation and Disease State.|
The purpose of this study is to determine whether serum resistin levels in asthmatics are elevated. We will recruit subjects from the allergy/immunology clinic with a prior diagnosis of moderate to severe persistent asthma in addition to subjects being seen for evaluation of drug allergies. Based on the inclusion and exclusion criteria below, subjects will be placed into a control and asthma group. Each subject will undergo one blood draw in the main lab at WHMC, and return a lavender top tube to the allergy/immunology clinic for the EIA resistin assay. The patient will then have a brief encounter with a physician to determine an up to date history of asthma symptoms prior to participating in the exhaled NO test. The entire subject encounter will take place with one clinic visit, and requires no follow up visits as part of the study. The greatest risk to each subject will be the blood draw, as the exhaled NO is a completely non-invasive test.
Plasma from each subject will be stored in a –70° freezer for no more than one month. Samples will be analyzed for resistin levels using an EIA assay run monthly. Mean values from serum CRP, serum glucose, serum resistin, and exhaled NO will be compared using a students T-test.
Resistin is part of the FIZZ (found in inflammatory zones) family of genes, and was first characterized in murine models where it has been extensively studied as a potential link between type II diabetes and obesity. The murine FIZZ gene family consists of three related gene products: a)FIZZ-1 or Relm-a is found in adipocytes and lung tissue, b)FIZZ-2 or Relm-b found in the gastrointestinal tract, and c)FIZZ-3 or Resistin also found in adipocytes.1 Mouse models have shown resistin to be linked to obesity and insulin resistance, and thiazolidinedione has been shown to decrease resistin expression in mouse adipocytes.2 Distribution of the FIZZ gene products in humans is similar to mouse models: a)Relm-a is found in adipose, heart, and lung, b)Relm-b is found in the gastrointestinal tract, and c)Resistin is found in adipocytes and interestingly, is also found in circulating macrophages.3 Given the findings correlating obesity with diabetes in the mouse model, several studies were done in humans attempting to illustrate this same link. A study comparing middle age type II diabetics with matched controls found serum resistin levels to be increased in the diabetic group (16.6 vs 13.5, p<0.004), but this elevation was independent of adiposity, BMI, or insulin resistance. Elevation in C-reactive protein (CRP) in the diabetic group was the only factor that consistently correlated with elevation in resistin levels in this study.4 A second study comparing older (60-75 years of age) type II diabetics also found a significant elevation in serum resistin in the diabetic group that was independent of gender, insulin resistance, BMI, blood pressure, or total cholesterol. Interestingly, this study did find an association with plasma glucose concentration and serum resistin levels.5 Although there seems to be no direct link between resistin and insulin resistance in humans, the above data suggest a role for insulin in systemic inflammation commonly associated with diabetes. Adipocytes are known to be a source of inflammatory cytokines such as TNF-a and IL-6. TNF-a has been shown to be elevated in obesity, and many acute phase reactants and cytokines are associated with diabetes and the metabolic syndrome.6 In addition, resistin has been shown to induce VCAM-1, ICAM-1, and long pentraxin 3 (markers of vascular inflammation) in mouse models. The resistin related induction of VCAM-1 was partially blocked with a statin, indicating a role for resistin in vascular inflammation that may contribute to atherosclerosis and coronary artery disease seen in diabetics and the metabolic syndrome.7 Given the effects on vascular inflammation, resistin may be an important cytokine involved in a common inflammatory pathway seen in both diabetics and asthmatics.
Like diabetes, asthma is a disease marked by chronic inflammation. The inflammation associated with asthma has been predominantly illustrated in the airways, however, studies have shown that induced bronchoconstriction and asthma do illicit a systemic response with elevations in CRP thought to be mediated by IL-1, IL-6, and TNF-a via activated macrophages.8,9 In addition, CCL2 contributes to airway hyper-reactivity and cell migration, and thiazolidinedione has been shown to inhibit the IL-1b and TNF-a induced expression of CCL2 in the lung.10 Finally, a recent study illustrated an IL-4 and IL-13 induction of Relm-b via STAT-6 in response to allergic asthma.11 The level of serum resistin in human asthmatics is currently unknown, and may represent an important systemic marker of inflammation in this disease. Relating levels of serum resistin with disease state in conjunction with measurements of serum CRP and glucose would be an important aspect of further understanding the potential systemic inflammatory implications of asthma. In addition, unpublished data on exhaled NO have shown a positive correlation with asthma that could be used to further strengthen evidence of systemic inflammation with airway inflammation.
|Study Design||Observational Model: Case Control
Observational Model: Natural History
Time Perspective: Cross-Sectional
Time Perspective: Prospective
|Target Follow-Up Duration||Not Provided|
|Sampling Method||Not Provided|
|Study Population||Not Provided|
|Study Groups/Cohorts||Not Provided|
|Publications *||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status||Unknown status|
|Estimated Completion Date||May 2006|
|Primary Completion Date||Not Provided|
|Ages||18 Years to 65 Years (Adult)|
|Accepts Healthy Volunteers||Yes|
|Contacts||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries||United States|
|Removed Location Countries|
|Other Study ID Numbers||FWH20040210H|
|Has Data Monitoring Committee||Not Provided|
|U.S. FDA-regulated Product||Not Provided|
|IPD Sharing Statement||Not Provided|
|Responsible Party||Not Provided|
|Study Sponsor||Wilford Hall Medical Center|
|PRS Account||Wilford Hall Medical Center|
|Verification Date||May 2006|